Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
Status:
Completed
Trial end date:
2011-01-20
Target enrollment:
Participant gender:
Summary
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical
antipsychotic medication, on negative symptoms in adult subjects with clinically stable
schizophrenia and predominant negative symptoms, as measured by the Scale for the Assessment
of Negative Symptoms (SANS).